Skip to content
2000
image of Prospective Clinical and Biochemical Evaluation of Breast Cancer in Patient Cohorts

Abstract

Introduction

Breast cancer is one of the most prevalent malignancies in women globally, characterized by diverse histological and molecular subtypes, each with varying clinical outcomes. Understanding these subtypes and their associated risk factors is critical for accurate diagnosis, prognosis, and treatment planning.

Methodology

The study scrutinized 187 breast cancer (BC) patients from Hail region of Saudi Arabia, focusing on ABO blood group distribution, histological type, cancer subtype, metastases size, age distribution, body mass index (BMI), gestational diabetes mellitus (GDM) status, and biochemical markers, including plasma calcium, magnesium, and HBA1C levels.

Results

Blood group distribution showed O+ (50.27%) as the most common blood type, followed by A+ (14.97%) and B+ (11.2%). Histologically, Invasive Ductal Carcinoma (IDC) accounts for 64.1% (120) cases, while Triple Negative Breast Cancer (TNBC) constitutes 17.1% (32) cases. The most common metastatic sites are the lungs (25.1%) and axillary lymph nodes (17.6%). HER2-positive breast cancer, seen in 9.1% of cases, can lead to multi-organ metastases in some cases. Age distribution indicated most patients were 46-55 years old (50 cases), while BMI data exhibited the highest frequency in the obese category (~90 cases), with 12 having GDM and 177 not having GDM. Calcium levels across age groups slightly fell below the typical adult range (2.1-2.6 mmol/L) with an average of around 2.06 mmol/L. Magnesium levels were elevated in patients less than 35 years of age (7.02 mmol/L) and were low in other groups. HbA1C levels in all age groups ranged from 6.44 to 6.67 mg/dL, aligning with prediabetic or diabetic thresholds. Plasma calcium and magnesium levels were elevated in the weight category, showing slight deviations from the normal range. Underweight patients displayed the lowest HbA1C levels with all weight categories exceeding 6.5 mg/dL, indicating diabetes.

Conclusion

The results highlight IDC as a predominant BC type, with O+ as the most common blood group among patients. TNBC remains a treatment challenge due to a lack of hormone receptors. Metastases mainly affect the lungs and lymph nodes. Elevated BMI, calcium, and magnesium levels correlate with increased HbA1C, suggesting a diabetic link. Emphasizing personalized treatment, obesity management, and electrolyte monitoring., the present research advocates a holistic approach for improved BC outcomes and suggests future exploration of metabolic influences.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ccdt/10.2174/0115680096369835250610135029
2025-11-27
2025-12-13

  • From This Site

    /content/journals/ccdt/10.2174/0115680096369835250610135029
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Benitez Fuentes J.D. Morgan E. de Luna Aguilar A. Mafra A. Shah R. Giusti F. Vignat J. Znaor A. Musetti C. Yip C-H. Van Eycken L. Jedy-Agba E. Piñeros M. Soerjomataram I. Global stage distribution of breast cancer at diagnosis: A systematic review and meta-analysis. JAMA Oncol. 2024 10 1 71 78 37943547
    [Google Scholar]
  2. Nambiar K. Evidence in Breast Cancer. Springer 2025 113 125
    [Google Scholar]
  3. Kuwata T. Molecular classification and intratumoral heterogeneity of gastric adenocarcinoma. Pathol. Int. 2024 74 6 301 316 10.1111/pin.13427 38651937
    [Google Scholar]
  4. Xiong X. Zheng L.W. Ding Y. Chen Y.F. Cai Y.W. Wang L.P. Huang L. Liu C.C. Shao Z.M. Yu K.D. Breast cancer: Pathogenesis and treatments. Signal Transduct. Target. Ther. 2025 10 1 49 10.1038/s41392‑024‑02108‑4 39966355
    [Google Scholar]
  5. Papalexis P. Georgakopoulou V.E. Keramydas D. Vogiatzis R. Taskou C. Anagnostopoulou F.A. Nonni A. Lazaris A.C. Zografos G.C. Kavantzas N. Thomopoulou G.E. Clinical, histopathological, and immunohistochemical characteristics of predictive biomarkers of breast cancer: A retrospective study. Cancer Diagn. Progn. 2024 4 3 340 351 10.21873/cdp.10330 38707726
    [Google Scholar]
  6. Abegaz S.B. Human ABO blood groups and their associations with different diseases. BioMed Res. Int. 2021 2021 1 6629060 10.1155/2021/6629060 33564677
    [Google Scholar]
  7. Gohar L. Riaz B. Nadeem M.S. Abbas S. Afsar T. Razak S. Muccee F. Husain F.M. Shafique H. Body mass index and altered lipid profile as major risk markers for breast cancer progression: A cross-sectional study of postmenopausal women in Pakistan. BMC Womens Health 2024 24 1 90 10.1186/s12905‑024‑02929‑z 38311739
    [Google Scholar]
  8. Mitaishvili E. Feinsod H. David Z. Shpigel J. Fernandez C. Sauane M. de la Parra C. The molecular mechanisms behind advanced breast cancer metabolism: Warburg effect, OXPHOS, and calcium. Front. Biosci. 2024 29 3 99 10.31083/j.fbl2903099 38538285
    [Google Scholar]
  9. Keesari P.R. Jain A. Ganampet N.R. Subhasri G.S.D. Edusa S. Muslehuddin Z. Theik N.W.Y. Palisetti S. Salibindla D. Manaktala P.S. Desai R. Association between prediabetes and breast cancer: A comprehensive meta-analysis. Breast Cancer Res. Treat. 2024 204 1 1 13 10.1007/s10549‑023‑07181‑x 38060076
    [Google Scholar]
  10. De Schepper M. Koorman T. Richard F. Christgen M. Vincent-Salomon A. Schnitt S.J. van Diest P.J. Zels G. Mertens F. Maetens M. Vanden Bempt I. Harbeck N. Nitz U. Gräser M. Kümmel S. Gluz O. Weynand B. Floris G. Derksen P.W.B. Desmedt C. Integration of pathological criteria and immunohistochemical evaluation for invasive lobular carcinoma diagnosis: Recommendations from the European lobular breast cancer consortium. Mod. Pathol. 2024 37 7 100497 38641322
    [Google Scholar]
  11. Wang J. Li B. Luo M. Huang J. Zhang K. Zheng S. Zhang S. Zhou J. Progression from ductal carcinoma in situ to invasive breast cancer: Molecular features and clinical significance. Signal Transduct. Target. Ther. 2024 9 1 83 10.1038/s41392‑024‑01779‑3 38570490
    [Google Scholar]
  12. Oesterreich S. Pate L. Lee A.V. Chen F. Jankowitz R.C. Mukhtar R. Metzger O. Sikora M.J. Li C.I. Sotiriou C. Shah O.S. Koorman T. Ulaner G. Reis-Filho J.S. Davidson N.M. Van Baelen K. Hutcheson L. Freeney S. Migyanka F. Turner C. Derksen P. Bear T. Desmedt C. International survey on invasive lobular breast cancer identifies priority research questions. NPJ Breast Cancer 2024 10 1 61 10.1038/s41523‑024‑00661‑3 39033157
    [Google Scholar]
  13. Riis M.L.H. The challenges of lobular carcinomas from a surgeon’s point of view. Clin. Breast Cancer 2024 24 8 e645 e654 10.1016/j.clbc.2024.06.007 39033066
    [Google Scholar]
  14. Stephan D. Prevalence of breast cancer subtypes and outcome in metastatic breast cancer patients diagnosed between 1984 and 2020.. Thesis, 2020
    [Google Scholar]
  15. Mustafa M. Abbas K. Alam M. Ahmad W. Moinuddin; Usmani, N.; Siddiqui, S.A.; Habib, S. Molecular pathways and therapeutic targets linked to triple-negative breast cancer (TNBC). Mol. Cell. Biochem. 2024 479 4 895 913 10.1007/s11010‑023‑04772‑6 37247161
    [Google Scholar]
  16. Fang Y. Zhang Q. Wu Y. Wu J. HER2-positive is an independent indicator for predicting pathological complete response to neoadjuvant therapy and Ki67-changed after neoadjuvant chemotherapy predicts favorable prognosis in Chinese women with locally advanced breast cancer. Medicine 2024 103 6 e37170 10.1097/MD.0000000000037170 38335419
    [Google Scholar]
  17. Simões R. Silva L.M. de Oliveira A.N. Alves M.T. Pestana R.M.C. de Souza I.D.P. Oliveira H.H.M. Soares C.E. Sabino A.P. Gomes K.B. Identification of clinical and laboratory variables associated with cardiotoxicity events due to doxorubicin in breast cancer patients: A 1-year follow-up study. Cardiovasc. Toxicol. 2021 21 2 106 114 10.1007/s12012‑020‑09600‑7 32844368
    [Google Scholar]
  18. Milani I. Gaita C. Guarisco G. Chinucci M. Parisella R. Piroli S. Bruno E. Martellucci A. De Falco E. Ricci F. Calogero A. Leonetti F. Capoccia D. The intricate relationship between obesity, type 2 diabetes and female breast cancer: A retrospective study of 335 women. Obes. Sci. Pract. 2024 10 4 e786 10.1002/osp4.786 39130194
    [Google Scholar]
  19. Natalicchio A. Marrano N. Montagnani M. Gallo M. Faggiano A. Zatelli M.C. Argentiero A. Del Re M. D’Oronzo S. Fogli S. Franchina T. Giuffrida D. Gori S. Ragni A. Marino G. Mazzilli R. Monami M. Morviducci L. Renzelli V. Russo A. Sciacca L. Tuveri E. Cortellini A. Di Maio M. Candido R. Perrone F. Aimaretti G. Avogaro A. Silvestris N. Giorgino F. Glycemic control and cancer outcomes in oncologic patients with diabetes: An Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), Italian Society of Pharmacology (SIF) multidisciplinary critical view. J. Endocrinol. Invest. 2024 47 12 2915 2928 10.1007/s40618‑024‑02417‑z 38935200
    [Google Scholar]
  20. Barbagallo M. Veronese N. Dominguez L.J. Magnesium in aging, health and diseases. Nutrients 2021 13 2 463 10.3390/nu13020463 33573164
    [Google Scholar]
  21. Cui H. Qu Y. Zhang L. Zhang W. Yan P. Yang C. Zhang M. Bai Y. Tang M. Wang Y. Chen L. Xiao C. Zou Y. Liu Y. Zhang L. Yang Y. Yao Y. Li J. Liu Z. Yang C. Jiang X. Zhang B. Epidemiological and genetic evidence for the relationship between ABO blood group and human cancer. Int. J. Cancer 2023 153 2 320 330 10.1002/ijc.34533 37074298
    [Google Scholar]
  22. Saxena S. Chawla V.K. Gupta K.K. Gaur K.L. Association of ABO blood group and breast cancer in Jodhpur. Indian J. Physiol. Pharmacol. 2015 59 1 63 68 26571986
    [Google Scholar]
  23. Corso G. Fusco N. Guerini-Rocco E. Invasive lobular breast can-cer: Focus on prevention, genetics, diagnosis, and treatment. Sem. Oncol. 2024 51 3-4 106 122 10.1053/j.seminoncol.2024.05.001
    [Google Scholar]
  24. Onkar S. Cui J. Zou J. Cardello C. Cillo A.R. Uddin M.R. Sagan A. Joy M. Osmanbeyoglu H.U. Pogue-Geile K.L. McAuliffe P.F. Lucas P.C. Tseng G.C. Lee A.V. Bruno T.C. Oesterreich S. Vignali D.A.A. Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironment. Nat. Can. 2023 4 4 516 534 10.1038/s43018‑023‑00527‑w 36927792
    [Google Scholar]
  25. Chaudhury S. Sau K. Khan M.A. Shabaz M. Deep transfer learning for IDC breast cancer detection using fast AI technique and Sqeezenet architecture. Math. Biosci. Eng. 2023 20 6 10404 10427 10.3934/mbe.2023457 37322939
    [Google Scholar]
  26. Dayan D. Lukac S. Rack B. Ebner F. Fink V. Leinert E. Veselinovic K. Schütze S. El Taie Z. Janni W. Friedl T.W.P. Effect of histological breast cancer subtypes invasive lobular versus non-special type on survival in early intermediate-to-high-risk breast carcinoma: Results from the SUCCESS trials. Breast Cancer Res. 2023 25 1 153 10.1186/s13058‑023‑01750‑0 38098086
    [Google Scholar]
  27. Cope W. Provenzano E. The diagnosis and management of lobular carcinoma in situ. Diagn. Histopathol. 2023 29 3 153 161 10.1016/j.mpdhp.2022.12.004
    [Google Scholar]
  28. Skarping I. Bendahl P-O. Szulkin R. Alkner S. Andersson Y. Bergkvist L. Christiansen P. Filtenborg Tvedskov T. Frisell J. Gentilini O.D. Kontos M. Kühn T. Lundstedt D. Vrou Offersen B. Olofsson Bagge R. Reimer T. Sund M. Rydén L. de Boniface J. Prediction of high nodal burden in patients with sentinel node–positive luminal ERBB2-negative breast cancer. JAMA Surg. 2024 159 12 1393 1403 39320882
    [Google Scholar]
  29. Xu K. Hua M. Mai T. Ren X. Fang X. Wang C. Ge M. Qian H. Xu M. Zhang R. A multiparametric MRI-based radiomics model for stratifying postoperative recurrence in luminal B breast cancer. J. Imaging Inform. Med. 2025 38 1 661 10.1007/s10278‑024‑01177‑9 38940892
    [Google Scholar]
  30. Yamsun M. Imaniah I. Maulana S.S. Setiawan R.H. Age and luminal type play important role as therapeutic policies in the management of breast cancer at Prof. Dr. Margono Soekarjo regional hospital Purwokerto. Int. J. Med. Sci. Clin. Res. Stud 2024 4 05 895 897 10.47191/ijmscrs/v4‑i05‑21
    [Google Scholar]
  31. Sun X. Tang H. Chen Y. Chen Z. Hu Z. Cui Z. Tao Y. Yuan J. Fu Y. Zhuang Z. He Q. Li Q. Xu X. Wan X. Jiang Y. Mao Z. Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer. Nat. Cancer. 2023 4 5 716 733 10.1038/s43018‑023‑00535‑w 37012401
    [Google Scholar]
  32. Itah Z. Chaudhry S. Raju Ponny S. Aydemir O. Lee A. Cavanagh-Kyros J. Tournier C. Muller W.J. Davis R.J. HER2-driven breast cancer suppression by the JNK signaling pathway. Proc. Natl. Acad. Sci. USA 2023 120 4 e2218373120 10.1073/pnas.2218373120 36656864
    [Google Scholar]
  33. Kyei K.A. Anim-Sampong S. Akoe E.A. Daniels J. Obeng-Mensah T. Antwi W.K. Ainuson-Quampah J. Radiation-induced dermatitis among breast cancer patients undergoing adjuvant radiotherapy in Ghana. Transl. Oncol. 2024 46 102028 10.1016/j.tranon.2024.102028 38861854
    [Google Scholar]
  34. Yang J.L. Hodara E. Sriprasert I. Shoupe D. Stanczyk F.Z. Estrogen deficiency in the menopause and the role of hormone therapy: Integrating the findings of basic science research with clinical trials. Menopause 2024 31 10 926 939 10.1097/GME.0000000000002407 39081162
    [Google Scholar]
  35. Montégut L. López-Otín C. Kroemer G. Aging and cancer. Mol. Cancer 2024 23 1 106 10.1186/s12943‑024‑02020‑z 38760832
    [Google Scholar]
  36. Nicolis O. De Los Angeles D. Taramasco C. A contemporary review of breast cancer risk factors and the role of artificial intelligence. Front. Oncol. 2024 14 1356014 10.3389/fonc.2024.1356014 38699635
    [Google Scholar]
  37. Obeagu E.I. Obeagu G.U. Breast cancer: A review of risk factors and diagnosis. Medicine 2024 103 3 e36905 10.1097/MD.0000000000036905 38241592
    [Google Scholar]
  38. B, S.S.; Narayanan, G.S.; Ps, A.; Br, K.K. Breast cancer in young women: Analysis of incidence, clinicopathological profile and biological behaviour in a tertiary care institute from South India. Asian Pac J. Cancer Biol. 2024 9 3 295 300 10.31557/apjcb.2024.9.3.295‑300
    [Google Scholar]
  39. Gado M. Tsaousidou E. Bornstein S.R. Perakakis N. Sex-based differences in insulin resistance. J. Endocrinol. 2024 261 1 e230245 10.1530/JOE‑23‑0245 38265844
    [Google Scholar]
  40. Engin A. Obesity-associated breast cancer: Analysis of risk factors and current clinical evaluation. Adv. Exp. Med. Biol. 2024 1460 767 819 10.1007/978‑3‑031‑63657‑8_26 39287872
    [Google Scholar]
  41. Varra F.N. Varras M. Varra V.K. Theodosis-Nobelos P. Molecular and pathophysiological relationship between obesity and chronic inflammation in the manifestation of metabolic dysfunctions and their inflammation mediating treatment options (Review). Mol. Med. Rep. 2024 29 6 95 10.3892/mmr.2024.13219 38606791
    [Google Scholar]
  42. Sweeting A. Wong J. Murphy H.R. Ross G.P. A clinical update on gestational diabetes mellitus. Endocr. Rev. 2022 43 5 763 793 10.1210/endrev/bnac003 35041752
    [Google Scholar]
  43. Gill G. Giannakeas V. Read S. Lega I.C. Shah B.R. Lipscombe L.L. Risk of breast cancer after diabetes in pregnancy: A population-based cohort study. Can. J. Diabetes 2024 48 3 171 178 10.1016/j.jcjd.2023.12.007 38160937
    [Google Scholar]
  44. Ranuncolo S.M. Armanasco E. Nuñez M. Yuan L. Makhkamov S. De Lorenzo M.S. Role of the serum levels of the inter-organs messenger fibroblast growth factor 21 (FGF21) in the diagnosis and prognosis of breast cancer patients. Cell Commun. Signal. 2025 23 1 37 10.1186/s12964‑024‑02003‑z 39838482
    [Google Scholar]
  45. Shah O.S. Nasrazadani A. Foldi J. Atkinson J.M. Kleer C.G. McAuliffe P.F. Johnston T.J. Stallaert W. da Silva E.M. Selenica P. Dopeso H. Pareja F. Mandelker D. Weigelt B. Reis-Filho J.S. Bhargava R. Lucas P.C. Lee A.V. Oesterreich S. Spatial molecular profiling of mixed invasive ductal and lobular breast cancers reveals heterogeneity in intrinsic molecular subtypes, oncogenic signatures, and mutations. Proc. Natl. Acad. Sci. USA 2024 121 31 e2322068121 10.1073/pnas.2322068121 39042692
    [Google Scholar]
  46. Jain H. Sinha A.K. Mathematical model of mixed invasive ductal and lobular breast cancer. Netw. Model. Anal. Health Inform. Bioinform. 2024 13 1 28 10.1007/s13721‑024‑00465‑2
    [Google Scholar]
  47. Hu Y. Wang C. Liang H. Li J. Yang Q. The treatment landscape of triple-negative breast cancer. Med. Oncol. 2024 41 10 236 10.1007/s12032‑024‑02456‑9 39210220
    [Google Scholar]
  48. Khalaji A. Hadad S. Sarmadian A.J. Ojaghlou F. Janagard E.M. Baradaran B. Advances in monoclonal antibody therapies for triple-negative breast cancer: Immunotherapeutic and targeted strategies. Curr. Mol. Med. 2024 10.2174/0115665240287767240115062343 38288828
    [Google Scholar]
  49. Szablewski L. Insulin resistance: The increased risk of cancers. Curr. Oncol. 2024 31 2 998 1027 10.3390/curroncol31020075 38392069
    [Google Scholar]
  50. Chew S.M. Liu B. Shen S. Iyengar N.M. The role of obesity and inflammation in breast cancer recurrence. Curr. Breast Cancer Rep. 2024 16 2 237 250 10.1007/s12609‑024‑00550‑5
    [Google Scholar]
  51. Saeed R.F. Awan U.A. Aslam S. Qazi A.S. Bhatti M.Z. Akhtar N. Micronutrients importance in cancer prevention-minerals. Cancer Treat Res. 2024 191 145 161 10.1007/978‑3‑031‑55622‑7_6 39133407
    [Google Scholar]
  52. Li M. Urologic Oncology: Seminars and Original Investigations. Elsevier 2024
    [Google Scholar]
  53. Yoo T.K. Lee M.Y. Lee S.A. Cheong E.S. Seo M.H. Sung K.C. Association of glycosylated hemoglobin level and cancer-related mortality in patients without diabetes. J. Clin. Med. 2022 11 19 5933 10.3390/jcm11195933 36233800
    [Google Scholar]
  54. Engin H. Bilir C. Üstün H. Gökmen A. ABO blood group and risk of pancreatic cancer in a Turkish population in Western Blacksea region. Asian Pac. J. Cancer Prev. 2012 13 1 131 133 10.7314/APJCP.2012.13.1.131 22502655
    [Google Scholar]
  55. Gates M.A. Xu M. Chen W.Y. Kraft P. Hankinson S.E. Wolpin B.M. ABO blood group and breast cancer incidence and survival. Int. J. Cancer 2012 130 9 2129 2137 10.1002/ijc.26220 21633955
    [Google Scholar]
  56. Ji H. Hu C. Yang X. Liu Y. Ji G. Ge S. Wang X. Wang M. Lymph node metastasis in cancer progression: Molecular mechanisms, clinical significance and therapeutic interventions. Signal Transduct. Target. Ther. 2023 8 1 367 10.1038/s41392‑023‑01576‑4 37752146
    [Google Scholar]
  57. Leong S.P. Witte M.H. Cancer metastasis through the lymphatic versus blood vessels. Clin. Exp. Metastasis 2024 41 4 387 402 10.1007/s10585‑024‑10288‑0 38940900
    [Google Scholar]
  58. Suryani D. Nuraini T. Gayatri D. Milanti A. Unraveling the link between self-efficacy and self-management in breast cancer patients during the COVID-19 pandemic: A cross-sectional study. Open Nurs. J. 2023 17 1 10.2174/0118744346267039231030104321
    [Google Scholar]
/content/journals/ccdt/10.2174/0115680096369835250610135029
Loading
Prospective Clinical and Biochemical Evaluation of Breast Cancer in Patient Cohorts
Bentham Science Publishers ; https://doi.org/10.2174/0115680096369835250610135029
/content/journals/ccdt/10.2174/0115680096369835250610135029
/content/journals/ccdt/10.2174/0115680096369835250610135029
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: Breast cancer ; GDM ; diabetes ; IDC ; TNBC ; HbA1C

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test